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Synopsis 
The concept of gene therapy is the introduction of the correct functional copies of 
the malfunctioning genes into cells to treat human diseases. For successful gene therapy 
an essential prerequisite is the development of safe and efficient gene delivery vectors. 
Although the objectives and principles of gene therapy had been well-defined several 
decades back, its application as a versatile, therapeutically successful approach has not 
yet met expectations. Gene therapy is expected to have a tremendous impact on the field 
of medicine, due to large number of diseases amenable to it and relative ineffectiveness 
of many current inventions. In principle any disease with a causative genetic component 
may be a candidate for gene therapy. With the recent completion of working draft of the 
human genome identifying disease targets for gene therapy are likely to dominate the 
field of medicine in the coming future. 
 Putting a new gene into a cell is a difficult job. DNA, the material that makes up 
genes, cannot be simply swallowed like a pill or even injected into the blood, as the 
unprotected DNA in the body is likely to be broken down, and any surviving DNA may 
not effectively recognize or enter the target cells for adsorption. DNA, being a 
polyanionic macromolecule, is not expected to spontaneously enter into our body cells as 
biological cell surfaces are negatively charged. A gene delivery vector needs to meet 3 
major criteria: [1] it should protect the transgene against degradation by nucleases in 
intercellular matrices, [2] it should bring the transgene across the plasma membrane and 
into the nucleus of target cells, and [3] it should have no detrimental effects. Thus, 
efficient delivery of genes into body cells (a process biologists call "transfection") is 
always easier said than done.  In other words, the problems of developing clinically 
viable gene therapeutic approach and designing safe & efficient gene delivery reagents 
are inseparable from each other: shortcomings in one is going to adversely affect the 
success of the other. Hence realization of the full potential of gene therapy will depend, 
in a major way, on the future development of safe and efficient gene delivery reagents. 
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Currently, there are three main types of gene delivery vectors commonly in use: viral, 
non-viral and physical methods. 
Viruses like retrovirus, adenovirus, adeno-associated viruses etc. have been 
extensively and successfully used as carriers of genes under in vitro and in vivo 
conditions. Recombinant vectors, although capable of ensuring high level gene 
expression have some major disadvantages like toxic inflammatory responses, possibility 
of random integration into host chromosome, systemic clearance of viral vectors due to 
complement activation, possibility of generating replication-competent virus through 
recombination with host genome, limited insert-size of the virally packaged therapeutic 
genes etc. 
All these serious bio-safety concerns associated with the use of viral vectors for 
gene delivery are increasingly making the non-viral gene delivery vectors as the alternate 
vectors of choice. Non-viral vectors like cationic amphiphiles, cationic polymers, and 
physical methods like electroporation, gene gun etc. are being used as viable alternatives 
to their viral counterparts.  
Among the existing arsenal of non-viral gene delivery vehicles, cationic 
liposomes, because of their biocompatibility, low immunogenicity, robust manufacture, 
ease in handling & preparation techniques, ability to inject large lipid-DNA complexes, 
etc. are finding widespread application in non-viral gene therapy. They are spherical 
bilayers composed of individual lipids enclosing a watery interior. Each lipid possesses a 
hydrophilic head group attached via a linker to a large hydrophobic domain. When 
exposed to an aqueous environment, these amphiphiles spontaneously form large 
spherical structures known as liposomes above a certain critical vesicular concentration 
(CVC).  Within the sphere, lipids are arranged back-to-back in bilayers with the polar 
hydrophilic group facing outwards shielding the hydrophobic domain from the aqueous 
solution. Liposomes may be unilamellar (composed of a single bilayer) or multilamellar 
(composed of many concentric bilayers). The multilamellar liposome (MLV) upon 
sonication followed by repeated extrusion through polycarbonate membranes of defined 
pore size assume the size of small unilamellar vesicle (SUV, 30-100 nm) or large 
unilamellar vesicle (LUV, 150-250 nm) (Figure 1).   
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 Figure 1.Formation of Liposomes. 
In liposomal gene delivery, cationic liposomes are mixed with DNA and the 
resulting electrostatic lipid-DNA complexes (popularly known as lipoplexes) are simply 
incubated with the cells (in vitro) or injected in animals (in vivo). If the DNA (containing 
the gene of interest) is taken up by cells via endocytosis and eventually reaches the 
nucleus, the gene coding the protein of interest is expressed through transcription and 
translation. Quantitative assay of the expressed protein indicates the success and 
efficiency of the procedure.  
 
 
Figure 2 .Lipofection Pathways 
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Currently believed lipofection (lipoplex mediated intracellular transfection) 
pathways involve: (a) formation of lipid/DNA complexes (b) initial binding of the 
lipoplex to the cell surface; (c) endocytotic internalization of the lipid:DNA complexes; 
(d) trafficking in the endosome/lysosome compartment and escape of DNA from the 
endosome/lysosome compartment to the cell cytoplasm; (e) involvement of cytoskeleton 
in translocation and dissociation of the DNA from the cationic lipid component (f) 
transport of the endosomally released DNA to the nucleus followed by its transgene 
expression (Figure 2).  
The molecular architectures of cationic amphiphiles consist of a positively 
charged water- loving polar head-group region and a non-polar hydrophobic tail region 
(usually consisting of either two long aliphatic hydrocarbon chains or a cholesterol 
skeleton) often tethered together via a linker functionality such as ether, ester, amide, 
amidine group, etc.  Understanding the structural parameters capable of influencing the 
gene delivery efficiencies of cationic transfection lipids is important. To this end, the 
focus of many prior structure-activity investigations have been centered around probing 
the influence of each of the above mentioned three lipid structural components in 
modulating the gene transfer efficacies of cationic amphiphiles.  For instance, a number 
of prior reports have demonstrated that the gene transfer efficiencies of cationic 
amphiphiles critically depends on their molecular architectures including hydrophobic 
alkyl chain-lengths, nature of head-groups as well as on the nature of linker and spacer 
functionalities used in covalent tethering of the polar head-groups and the non-polar tails 
of cationic amphiphiles. 
Previously we demonstrated dramatic influence of linker orientation between 
hydrophilic and hydrophobic moieties in modulating efficacies of cationic amphiphiles in 
delivering genes into cultured animal cells. In this previous work two cationic lipids 1 & 
2 (Figure 3) were designed and synthesized with remarkably similar molecular 
architecture. Both lipid 1& 2 contain the same hydrophilic head group, the same 
hydrophobic tail, the same ester linker functionality, the only structural difference 
between lipid 1& 2 is the orientation of the ester linker functionality. The covalent bond 
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between the ester carbonyl group and the quarternized nitrogen atom in lipid 2 was 
shorter than that in lipid 1 by one sigma bond length. This was the sole structural 
difference between lipids 1& 2. While lipid 1 was shown to be transfection efficient in 
cultured cells. Lipid 2 was found to be essentially transfection incompetent. The 
mechanistic origin of such contrasting transfection properties of lipids 1 & 2 were 
attributed to significantly higher biomembrane fusogenecities of the liposomes of lipid 1. 
However despite such dramatic in vitro gene transfer efficacies of lipids 1 & 2, both the 
lipid failed to delivergenes under systemic settings (unpublished work) presumably due 
to assault by systemic esterases. Since ester functionality chemically more labile than the 
amide functionality, in the present thesis, I have designed and synthesized the amide 
analogs of lipid 1 & 2 namely lipids 3 & 4, toward first experimental demonstration of 
influence of linker orientation under systemic settings. 
As in case of lipids 1& 2, chapter 1 delineates the only structural difference 
between the cationic amphiphiles 3&4 is the orientation of their linker amide function. 
Synthesis, dramatically contrasting in vitro gene delivery efficacies as well as in vivo 
gene delivery efficacies and physiochemical properties of these two novel cationic lipids 
containing amide linker. The findings presented in chapter 1 provides the first 
experimental for the extension of linker orientation influence under systemic settings in 
liposomal gene delivery. 
 
N
HN NH
C C
C13H27 C13H27
OO
OH
H3C +
Cl-
Lipid 3
N
C C
NH NH
C13H27 C13H27
OH
H3C +
Cl-
Lipid 4
OO
N
O O
C C
C13H27 C13H27
OO
OH
H3C +
Cl-
Lipid 1
N
C C
O O
C13H27 C13H27
OH
H3C +
Cl-
Lipid 2
OO
A. B.
 
Figure 3. Structure of the cationic amphiphiles differing only in the orientation of the linker functionality. 
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Cationic liposomes bearing various covalently grafted receptor specific ligands 
(the so-called “homing” device) are capable of delivering their genetic pay-loads to 
specific body cells. Perhaps, the most successful uses of cationic transfection lipids have 
been demonstrated for targeting genes to liver cells (hepatocytes).   Interestingly, design 
of many of the previously reported liver-specific cationic glyco-lipid based transfection 
vectors has been based on the covalent grafting of only the cyclic pyranose form of the 
galactose ligands into their polar head-group regions. To this end, being inspired by our 
previous findings that cationic glycolipids with open-sugar heads are also capable of 
efficiently transfecting cultured cells in vitro, we decided to explore an hitherto 
unexplored structure-function issue in the area of cationic glycol-lipid mediated gene 
delivery:  Relative transfection properties of cationic glycolipids with cyclic and open 
form of sugar head groups. The findings of this important structure-activity study 
involving the use of number of novel cationic  glycolpids. Lipids 1-5 (Figure 4) 
containing the cyclic pyranose form of  D-Galactose sugar head at varying covalent bond 
distances between the pyranose form of D-Galactose and the quaternized   nitrogen center 
and lipids 6-10 ( Figure 4) with varying covalent bond distances between the open form 
of D-Galactose and the quaternized   nitrogen center. Lipids 11 & 12 (Figure 4) 
containing the cyclic pyranose form  and open sugar form of  D-Galactose sugar heads as 
the same covalent bond distances from the quaternized   nitrogen center.  
 
 
 
 
 
 
 
 
Figure 4: Chemical structures of glycolipids with cyclic and open of the sugar heads. 
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Lipids 1-10 contained aliphatic n-hexadecyl chain as their hydrophobic tail and 
their synthesis have been carried out by another senior doctoral student (Dr.M.Rajesh ) 
from our lab. Toward probing structure-activity issue for cationic glycolipids with 
cholesterol as hydrocarbon tail, Chapter 2 describes design, synthesis and relative in 
vitro and in vivo  transfection properties of  two novel cationic glycolipids 11 &12 
(Figure 5) with cholesterol as hydrophobic tail. 
In summary the in vitro and in vivo structure activity findings described in chapter 
2 are consistent with the supposition that for cationic glycolipids with n-hexadecyl 
hydrophobic tail, the optimal covalent bond distance between the quaternized nitrogen 
center and pyranose sugar head is higher than that between the quaternized nitrogen 
center and open chain D-Galactose sugar head. Between the two cholesterol containing 
cationic glycolipids 11 & 12 (Figure 5), lipid 11 with pyranose form of D-Galactose 
head was found to be more transfection efficient. In addition, chapter 2 also describes the 
serum compatibilities and biomembrane fusgenecities of these novel series of cationic 
glucolipids. 
 
 
 
 
 
 
 
 
 
 
Figure 5: Chemical structures of  Cholesterylated glycolipids with cyclic and open of the sugar heads. 
 
Congestive heart failure (CHF), or heart failure, is a condition in which the heart 
can't pump enough blood to the body's other organs. Brain natriuretic peptide (BNP), also 
known as B-type natriuretic peptide or GC-B, is an endogenous peptide/a neurohormone 
that belongs to a family of peptides that are involved in cardiovascular, renal, and 
endocrine homeostasis. It is released as a preproBNP peptide of 134 amino acids and is 
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cleaved into proBNP (108 amino acids)and a signal peptide of 26 amino acids. ProBNP is 
subsequently cleaved into BNP (32 amino acids) with one disulphide bond and the 
inactive N-Terminal proBNP peptide (NT-proBNP; 76 amino acids). The release of BNP 
into the circulation is directly proportional to the ventricular expansion and volume 
overload of the ventricles and therefore reflects the decompensated state of the ventricles.  
Brain Natriuretic peptide upon binding to NPR-A/B activates intracellular signalling 
cascade by activating the guanylylcyclase enzyme. Guanylylcyclase converts GTP 
(guanosine triphosphate) into cGMP (cyclic-guanosine monophosphate), considered an 
intracellular second messanger, which inturn activates cGMP dependent protein kinase 
(PKC). Activated cGMP dependent protein kinases further phosphorylates different 
proteins leading to the physiological response i: e vasodilatation 
Human brain natriuretic peptides(hBNPs) are curently used as a drug for treating  
congestive heart failure. The subcutaneous administration of hBNP leads to an increase in 
the plasma BNP levels. However the proteolytic degradation of these hBNP molecules 
leads to decrease in the efficacy/bioavailability of the BNP molecules. Native BNP 
molecule has a relatively short half-life in circulation; and they are hydrolysed by neutral 
endopeptidases. The circulating half life of BNP is approximately 20 minutes. Already 
known BNPs are administered intravenously, usually by bolus, followed by intravenous 
(i.v.) infusion. For most adults and the elderly, a normal dosage is 2 µg/kg  followed by a 
continuous IV infusion of 0.01 µ/kg/minute. This may be increased every three hours for 
a maximum of 0.03 µg/kg/min. Thus, there is a need for frequent injection of hBNP drug 
over a long therapeutic period. Use of liposome containing encapsulated rhBNP  
improves the bioavailablity of the BNP and imparts a longer half-life to circulating BNP 
molecules. Chapter 3A describes development of two novel liposomal BNP 
formulations containing equimolar of  N,N-di tetradecyl-N,N-di-2-hydroxyethyl 
ammonium chloride (DTDEAC), Cholesterol (Figure 6) and a newly synthesized 
circulation enhancer lipid called DSPE-PEG-Octaarginine (Figure 6) as a minor 
component (5 mol% w.r.t. DTDEAC and Cholesterol). Findings described in chapter-3a 
demonstrate the therapeutic potential of our novel liposomal formulation of rhBNP for 
treatment of congestive heart failure. 
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Figure 6: Chemical structures of lipids used in BNP delivery. 
 
Toward probing the therapeutic potential of gene therapy in combating congestive heart 
failure, in collaboration with the scientists of Virchow Biotech Pvt.Ltd. Hyderabad, we 
cloned a plasmid encoding full length BNP gene sequence in a mammalian expression 
vector pCDNA 3.1. The findings delineated in Chapter-3B demonstrate for the first time 
the promise of non-viral gene therapy approach for the treatment of congestive heart 
failure. 
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